There is growing litigation related to the medication Dupixent and its potential link to cutaneous t-cell lymphoma, a type of cancer. Some reports suggest that Dupixent may be associated with an increased risk of lymphoma, while also noting potential benefits such as lower all-cause mortality in asthma patients. Patients are being advised to learn about their rights and the potential risks associated with Dupixent, with various lawsuits and settlement information being made available.